Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Acrivon Therapeutics to post earnings of ($0.66) per share for the quarter.
Acrivon Therapeutics Stock Performance
Shares of ACRV stock traded up $0.22 on Friday, reaching $5.36. 64,738 shares of the company were exchanged, compared to its average volume of 250,253. Acrivon Therapeutics has a 1 year low of $4.69 and a 1 year high of $11.90. The business has a 50-day moving average price of $5.54 and a 200 day moving average price of $6.68. The company has a market cap of $166.89 million, a price-to-earnings ratio of -1.99 and a beta of 0.85.
Analyst Ratings Changes
Several research firms have commented on ACRV. KeyCorp initiated coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an "overweight" rating for the company. Cantor Fitzgerald assumed coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an "overweight" rating for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $23.67.
Check Out Our Latest Report on Acrivon Therapeutics
Acrivon Therapeutics Company Profile
(
Get Free Report)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Articles
Before you consider Acrivon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.
While Acrivon Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
